 The point of care technologies are important in our particular area of interest, which is low resource settings, because many times people come with symptoms of a disease, travel many miles, kilometers down the road, often down a path, unpaved roads, perhaps carrying their children, missing a day of work to get a diagnostic and treatment. And point of care technologies are very important because without them that sample that's taken that day may have to travel days to go to a laboratory for results. That person goes back to their village with their child and perhaps is never seen again for treatment once those results come in. So our objective with some of the technologies we're working on is to really bring that much closer so the diagnosis and treatment happens at the point of care so that those people can go back to their communities treated and get back on with their lives quickly. We've been working on a platform called NIA, stands for non-instrumented nucleic acid amplification and the whole reason for this technology coming to being is because a lot of the worst diseases that plague say sub-Saharan Africa, for example HIV and malaria are two really good examples, occur superimposed with a map of the least electricity available, density, you know, there's just not a lot of electricity available in these areas. And so the traditional means of high accuracy diagnostics just aren't available to the majority of people in some of the areas that we're most concerned about at PATH. The core technology is called chemical temperature control. So what's happening with our NINA core technology is that we're using a chemical reaction to exothermically create heat. We create a nice stable temperature profile for the chemical reaction by thermally coupling that with what's called an engineered phase change material and as long as we have two phases we can achieve isothermal temperatures. What happens in the process of a person coming into a clinic is they give a very small sample through a finger prick so 50 to 100 microliters of blood will go into a test room that has what we call the master mix of all of the reagents necessary to amplify RNA and DNA. That requires heat so that master mix will then go into our chemical heater for 30 to 60 minutes and then the results are another technology that requires electricity free detection and we're pairing the NINA technology with some of the most innovative detection technologies that are out there.